TERNS
LIVE

Serial Number

99328453

Owner

Terns Pharmaceuticals, Inc.

Attorney

Tiffany D. Gehrke

Filing Date

Aug 8, 2025

Add to watchlist:

No watchlists yet
View on USPTO

TERNS Trademark

Serial Number: 99328453

TERNS is a trademark filed by Terns Pharmaceuticals, Inc. on August 8, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Terns Pharmaceuticals, Inc. (3 trademarks)

1065 East Hillsdale Blvd., Suite 100
Foster City, CA 94404

Entity Type: 03

Trademark Details

Filing Date

August 8, 2025

Registration Date

Not Registered

Published for Opposition

February 10, 2026

Goods & Services

Pharmaceutical preparations, namely, small-molecule drugs for the treatment of cancer, metabolic disorders, and endocrine disorders; Pharmaceutical and biologic preparations for use in the treatment of oncology-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of metabolic-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of endocrine-related diseases and disorders; Pharmaceutical and biologic preparations for use in the treatment of diabetes and obesity-related diseases and disorders; Peptides for pharmaceutical purposes, namely, for the treatment of cancer, metabolic disorders, and endocrine disorders

Pharmaceutical and biologic drug development services, namely, development of small-molecule drugs for use in humans; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of oncology-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of metabolic-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of endocrine-related diseases and disorders; Pharmaceutical and biologic drug development services, namely, development of pharmaceutical and biologic preparations for the treatment of diabetes and obesity-related diseases and disorders; Research and development services in the field of pharmaceutical and biologic preparations; Research and development services in the field of oncology-related diseases and disorders; Research and development services in the field of metabolic-related diseases and disorders; Research and development services in the field of endocrine-related diseases and disorders; Research and development services in the fields of diabetes and obesity-related diseases and disorders; Research and development services in the field of peptide pharmaceutical preparations; Providing medical and scientific research information in the field of small-molecule drugs; Providing medical and scientific research information in the field of clinical trials and post-market trials; Providing medical and scientific research information in the field of oncology, metabolic, endocrine, diabetes, and obesity-related diseases and disorders

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 7, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 4, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 15, 2026 CNSA
ASSIGNED TO EXAMINER
Jan 8, 2026 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jan 7, 2026 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 7, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Aug 8, 2025 MAFR
NEW APPLICATION ENTERED
Aug 8, 2025 NWAP